Researchers Showcase Potentially Curative Treatment in DLBCL

NIH researchers have developed a novel five-drug combination therapy, dubbed ViPOR, that targets essential survival pathways in relapsed or refractory DLBCL. The regimen demonstrated significant efficacy, with 54% of patients experiencing tumor reduction and 38% achieving complete remission and lasting responses.